Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO

Oliva-Damaso, N., & Bomback, A. S. (2021). Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO. Kidney360, 2(11), 1696–1698. https://doi.org/10.34067/kid.0001842021
Authors:
Nestor Oliva-Damaso
Andrew S Bomback
Affiliated Authors:
Andrew S Bomback
Columbia Affiliation:
Subjects:
Glomerulonephritis, Membranous (MeSH)
Author Keywords:
cyclophosphamide
glomerular and tubulointerstitial diseases
immunosuppressive agents
membranous glomerulonephritis
rituximab
elink
Publication Type:
Article
Unique ID:
10.34067/kid.0001842021
PMID:
35373001
DOI:
10.34067/kid.0001842021
Journal:
Kidney360
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: